DDInter909 DDInter504
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]
Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as desipramine and nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline and doxepine. TCAs also down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H<sub>1</sub> receptors, &alpha;<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Desipramine exerts less anticholinergic and sedative side effects compared to tertiary amine TCAs, such as amitriptyline and clomipramine. Desipramine may be used to treat depression, neuropathic pain (unlabeled use), agitation and insomnia (unlabeled use) and attention-deficit hyperactivity disorder (unlabeled use).
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promazine
Promazine {u} (Compound) resembles {v} (Compound) Desipramine
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Protriptyline
Protriptyline {u} (Compound) resembles {v} (Compound) Desipramine
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alimemazine
Alimemazine {u} (Compound) resembles {v} (Compound) Desipramine
Imatinib {u} may lead to a major life threatening interaction when taken with {v} Carbamazepine
Carbamazepine {u} (Compound) resembles {v} (Compound) Desipramine
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxcarbazepine
Oxcarbazepine {u} (Compound) resembles {v} (Compound) Desipramine
Imatinib {u} (Compound) binds {v} (Gene) SLC22A2
SLC22A2 {u} (Gene) is bound by {v} (Compound) Desipramine
Imatinib {u} (Compound) downregulates {v} (Gene) HAT1
HAT1 {u} (Gene) is downregulated by {v} (Compound) Desipramine
Imatinib {u} (Compound) causes {v} (Side Effect) Disturbance in sexual arousal
Disturbance in sexual arousal {u} (Side Effect) is caused by {v} (Compound) Desipramine
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promazine
Promazine {u} (Compound) resembles {v} (Compound) Triflupromazine
Triflupromazine {u} (Compound) resembles {v} (Compound) Desipramine
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Protriptyline
Protriptyline {u} (Compound) resembles {v} (Compound) Atomoxetine
Atomoxetine {u} (Compound) resembles {v} (Compound) Desipramine
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Desipramine (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Protriptyline and Protriptyline (Compound) resembles Desipramine (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Desipramine (Compound)
Imatinib may lead to a major life threatening interaction when taken with Carbamazepine and Carbamazepine (Compound) resembles Desipramine (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine (Compound) resembles Desipramine (Compound)
Imatinib (Compound) binds SLC22A2 (Gene) and SLC22A2 (Gene) is bound by Desipramine (Compound)
Imatinib (Compound) downregulates HAT1 (Gene) and HAT1 (Gene) is downregulated by Desipramine (Compound)
Imatinib (Compound) causes Disturbance in sexual arousal (Side Effect) and Disturbance in sexual arousal (Side Effect) is caused by Desipramine (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Triflupromazine (Compound) and Triflupromazine (Compound) resembles Desipramine (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Protriptyline and Protriptyline (Compound) resembles Atomoxetine (Compound) and Atomoxetine (Compound) resembles Desipramine (Compound)